THX Pharma maintains its financial stability as of June 30, 2026

On July 9, 2026, THX Pharma reported its cash position of €17.5 million as of June 30, 2026. This amount reflects a slight decrease compared to the pro forma cash position of €19.9 million recorded as of March 31, 2026, which took into account the €2.4 million VAT refund in April.

This financial development is part of the company's strategic implementation, which focuses on launching Phase 3 of the Batten-1 program for Batten disease. Biocodex is covering the clinical development costs, thus providing long-term financial security.

CEO Mathieu Charvériat highlights the key milestones achieved during the semester, including the approval of the EMA's Pediatric Committee for TX01, guaranteeing up to ten years of commercial protection in Europe.